| Document |
Document Title |
|
WO/2021/023733A1 |
The invention relates to a nanoparticle preparation comprising nanoparticles of well-defined and reproducible sizes, that are substantially free of aggregate formation.
|
|
WO/2021/023915A1 |
Antibiotic for use in a method comprising systemically administering a photosensitive antibiotic to a subject having a microbial infection in a target tissue to provide a blood plasma concentration of the antibiotic in the subject; allow...
|
|
WO/2021/021499A1 |
The present disclosure relates to a novel nano-droplet composition comprising a fluorocarbon core and a polymeric shell, and the method of using and making the novel nano-droplet composition. The fluorocarbon core and the polymeric shell...
|
|
WO/2021/018898A1 |
The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by ionizing radiations in a subject in need thereof, said method comprising the steps of: (i) injecting a first ...
|
|
WO/2021/019268A1 |
The disclosure relates to methods for treating tumors. In particular, the disclosure relates to a method of treating a tumor by ionizing radiations in a subject in need thereof, said method comprising the steps of: (i) injecting a first ...
|
|
WO/2021/021882A1 |
The present disclosure relates to near-infrared (NIR) photoimmunotherapy (PIT) for treating a subject having a cancer, such as a cancer comprising a first tumor or a primary tumor, metastatic tumor cells and/or invasive tumor cells. The ...
|
|
WO/2021/019253A1 |
Described herein are processes and compositions for ultrasound-triggered liposome payload release, including a process for gelation and a process for enzyme catalysis.
|
|
WO/2021/010698A1 |
The present invention relates to a cancer cell-targeted drug delivery carrier, a composition for promoting photo-thermal treatment effects, and the like, which contain M1 macrophages as an active ingredient. The drug delivery carrier of ...
|
|
WO/2021/009450A1 |
The present invention relates to the field of enhancing the bioavailability of active compounds. More particularly, it relates to a method for enhancing the bioavailability of hydrophilic active compounds in solution in an aqueous medium...
|
|
WO/2021/009623A1 |
Liquid formulation including a photo-sensitizing agent and an oxidizing agent, in particular for the treatment of eye disorders.
|
|
WO/2021/003567A1 |
The present technology relates to a biophotonic system comprising at least one chromofilm; and a light-emitting support operably connectable to the chromofilm. Operable connection of the light-emitting support and the at least one chromo...
|
|
WO/2021/004053A1 |
Disclosed are the use of titanium dioxide in the preparation of a device for preventing and/or treating breast cancer, and a brassiere for inhibiting the growth of breast cancer cells through proto-oncogene protein resonance. The materia...
|
|
WO/2021/003568A1 |
The present disclosure generally relates to silicone-coated biophotonic material and to articles comprising same as well as to the potential uses thereof, such as, for example, in wound treatment.
|
|
WO/2020/259489A1 |
A preparation method for a silk fibroin/manganese dioxide composite microsphere drug carrier having a core-shell structure, comprising: (1) adding a water-soluble organic solvent to an aqueous solution of silk fibroin, performing freezin...
|
|
WO/2020/260938A1 |
The present invention provides compositions, methods and kits for treating acne and other skin conditions influenced by C. acnes, which combine administration of low levels of at least one substituted resorcinol and blue light to skin in...
|
|
WO/2020/264034A1 |
Systems and methods for controlling energy delivered for thermal ablation. An apparatus may include a conductive member comprising an array of conductive filaments, a power supply configured to provide the current to the conductive/resis...
|
|
WO/2020/261199A1 |
The present invention relates to a phage or a composition that comprises it, wherein said phage expresses at least one specific recognition element and is furthermore conjugated with at least 300 molecules of a sonosensitiser. The invent...
|
|
WO/2020/252331A1 |
Methods are provided for the treatment of cancer or neoplastic diseases and the like, by administering 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-
1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluoro-benzonit
rile (compou...
|
|
WO/2020/251202A1 |
The present invention relates to highly dispersible zinc phthalocyanine (ZnPc)-silica nanotubes, and a preparation method therefor, and, more specifically, to: highly dispersible ZnPc-silica nanotubes, which improve the dispersibility of...
|
|
WO/2020/249953A1 |
The invention provides a method of preparing a microbubble covalently attached to at least one therapeutic agent which comprises: (i) providing a lipid (e.g. a phospholipid) capable of forming a microbubble; covalently linking at least o...
|
|
WO/2020/246350A1 |
This bactericide contains a conjugate (10) in which a photosensitizer (12) is bound to an antibody (11). In the conjugate (10), the antibody (11) causes an antigenâantibody reaction with Staphylococcus aureus (16). Moreover, the absorp...
|
|
WO/2020/244600A1 |
Disclosed is a method for preparing a medical titanium implant with the function of eliminating a surface bio-membrane. The method comprises the following steps: firstly, synthesizing mesoporous dopamine (MPDA) nanoparticles by means of ...
|
|
WO/2020/246913A1 |
The group of inventions relates to the field of medicine, and specifically to methods of producing compositions for boron neutron capture therapy of malignant tumors, said compositions containing boron nanoparticles less than 100 nm in s...
|
|
WO/2020/244570A1 |
Disclosed are a photosensitizer represented by general formula (I), a preparation method for the photosensitizer and an application thereof in tumor photodynamic therapy and tumor imaging diagnosis. In the photosensitizer, folic acid as ...
|
|
WO/2020/247598A1 |
This disclosure relates to compositions and uses of caged proteins substituted with a photon decomposing chemical structure wherein the photon decomposing chemical structure is substituted through a linking group to a hydrophilic polymer...
|
|
WO/2020/243671A1 |
Disclosed herein are methods of vaccination against cancer by providing a sample of a photo-inactivated Leishmania optionally transgenically modified to express a cancer antigen such as alpha-enolase; optionally providing an effective am...
|
|
WO/2020/242234A1 |
The present invention relates to an injectable pharmaceutical composition containing a prodrug of caspase inhibitors, and a preparation method therefor. More specifically, the present invention relates to an injectable pharmaceutical com...
|
|
WO/2020/242971A1 |
Embodiments provide methods and apparatus for fabricating blood products, such as platelet-rich plasma, containing elevated concentrations of growth factors such as platelet derived growth factor. The platelet-rich plasma can be autologo...
|
|
WO/2020/243319A1 |
An improved method for MRI-guided sonosensitized focused ultrasound treatment of malignant tissue is disclosed herein.
|
|
WO/2020/240590A1 |
Devices, systems and methods for controlling motion of magnetic-driven nanobots are provided. Based on a selection indicative of a pattern of movement of the nanobots (200), a signal can be generated indicative of a pattern of magnetic f...
|
|
WO/2020/243390A1 |
Provided herein are compositions, systems, kits, and methods for administering a gel composition into a tumor of a subject and treating with laser light (e.g., for photoacoustic destruction of the tumor and tumor debris generation), wher...
|
|
WO/2020/242051A1 |
Disclosed are: a compound; a composition comprising the compound; and a photodynamic therapy method for inactivating or killing tumor cells using the composition.
|
|
WO/2020/233437A1 |
The present invention belongs to the technical field of medicine, and relates to use of a diketone compound in photodynamic therapy or diagnosis. In particular, the present invention relates to use of a compound as shown in formula (I), ...
|
|
WO/2020/234832A1 |
The disclosure comprises a formulation comprising a gene edition enzyme, upconversion nanoparticles, which convert near-infrared light into visible light; at least one photo-cleavable linker and immobilized hydroxychloroquine at the surf...
|
|
WO/2020/230084A1 |
The present application relates to a triggerable polymeric nanoparticle (NP) library composed by several formulations, presenting physico-chemical diversity and differential responsiveness to light. In certain applications, six formulati...
|
|
WO/2020/231236A1 |
Disclosed, according to one embodiment, is a photodynamic therapy method mediated by a chlorin e6 photosensitizer composite for treating and preventing obesity, the method comprising the steps of: injecting or administering a chlorin e6 ...
|
|
WO/2020/229878A1 |
A composition for photodynamic therapy which comprises a photosensitiser in combination with ethylenediaminetetraacetic acid (EDTA) and epigallocatechin galate (EGCG), in pharmacologically acceptable carriers and/or excipients. The photo...
|
|
WO/2020/232133A1 |
Aspects of the technology described herein are directed to a method of treating gastrointestinal cancer in a subject. This method involves selecting a subject, where the subject (i) has been diagnosed with a gastrointestinal cancer and (...
|
|
WO/2020/223813A1 |
There is described herein a nanoparticle comprising an outer shell comprising a porphyrin salt, an expanded porphyrin salt or an analog of porphyrin salt, around an inner oil core.
|
|
WO/2020/224780A1 |
The present application discloses para-aminohippuric acid (PAH) or a pharmaceutically acceptable salt or carboxylic acid derivate thereof for use in a method for the reduction of nephrotoxic side effects of radiolabeled and non-radiolabe...
|
|
WO/2020/225447A1 |
The present application discloses para-aminohippuric acid (PAhI) or a pharmaceutically acceptable salt or carboxylic acid derivate thereof for use in a method for the reduction of nephrotoxic side effects of radiolabeled and non-radiolab...
|
|
WO/2020/222133A1 |
The present invention relates to a method for producing ferrite nanocrystals, comprising the following steps: i) providing a solution comprising a fatty acid, an aliphatic amine and an alcoholic solvent; ii) adding at least one organomet...
|
|
WO/2020/217205A1 |
The present invention relates to a method for increasing the release of at least one compound, said compound being initially an initial compound bound to at least one initial nanoparticle, said initial compound bound to said initial nano...
|
|
WO/2020/218993A1 |
The invention relates to a toothpaste used in the cosmetic and health sectors, which differs from conventional toothpastes currently in use, with protecting human health by more effectively destroying microorganisms such as bacteria, vir...
|
|
WO/2020/218562A1 |
Provided are a pharmaceutical composition for treating or preventing drug-resistant cancer by photodynamic therapy (PDT) that contains 5-aminolevulinic acid (ALA) or a derivative thereof, or a salt of these, and a method for treating or ...
|
|
WO/2020/217472A1 |
Provided are: a medicinal composition for treating or preventing a drug-tolerant cancer using photodynamic therapy (PDT), said composition comprising 5-aminolevulinic acid (ALA), a derivative thereof or a salt of the same; and a method f...
|
|
WO/2020/219556A1 |
A stem cell therapy using an energy field (e.g., a laser beam) to prime stem cells, and then using a matching energy field to direct the primed stem cells to a target tissue. Preferably, the matching energy field has the same frequency a...
|
|
WO/2020/210712A2 |
A nanocomposition for use in treating a cardiac condition using phthalocyanine dye, such as IR700. A nanocomposition having IR700, an 8PEG nanoparticle and a cardiac targeting peptide. Administering a product comprising IR700 to a patien...
|
|
WO/2020/204105A1 |
[Problem] To provide a novel cell activator. [Solution] Provided are: a cell activator containing a wavelength conversion substance as an effective component thereof; a composition and a product that contain the cell activator; and a met...
|
|
WO/2020/204195A1 |
Provided is a novel composition that contains an ultraviolet wavelength-converting substance and a powder of hydrophobized silica and/or hydrophobized starch.
|
